Skip to main content
OpenTrials
Completed

NCT Number: NCT01734915

Detecting EGFR T790M Mutations From Circulating Tumor Cells

The purpose of this research study is to determine if the EGFR mutation can be detected in CTCs. CTCs are cancer cells that are shed from solid tumors and float freely in the bloodstream. A device called the CTC-chip has been developed to find CTCs in the blood of patients with cancer. This is an experimental device. Using this device, the investigators will test participants' blood to try and find CTCs with the EGFR mutation and compare them with the results from the biopsy your doctor has recommended. The long-term goal of this research is to develop a way to test for the EGFR mutation that is less invasive than a tumor biopsy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Non Small Cell Lung Cancer Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Loading trial locations.

About this study

In order to participate in this study you need to have a diagnosis of NSCLC that has spread or is unable to be surgically removed. In addition, your cancer must have an EGFR mutation and you must have a scheduled (or recently performed) biopsy to check on the presence of any other mutations related to targeted drug resistance.

After you sign consent to participate in this study we will draw a blood sample (three tubes of blood). This is about 6 teaspoons of blood.

The number of CTCs in your blood will not be reported to you since it is not known if this number has any meaning or if it impacts your medical care in any way. These results will not become part of your medical record. They will be kept in a separate, secure location.

We will collect information from your medical records and store it in a research record that we create about you. The study team will use this information to compare details about your medical history with the results of the experiments done on your blood.

Genetic material (DNA) will be removed from the CTCs found in your blood. This genetic material will be stored at the Massachusetts General Hospital and studied along with samples from other participants on this research study. Your samples will not be labeled with your name or any information that identifies you. Your samples will have a study-specific code number on them. The code linking your name to the sample will be kept in a secure location, available only to the investigators of the study and select study team members.

After the blood draw we will follow your status every 6 months by reviewing your medical records.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically confirmed NSCLC that is metastatic or unresectable
  • Have agreed to undergo a clinically recommended invasive repeat tumor itssue biopsy

Exclusion criteria

-

Treatment and study plan

Circulating tumor cell chip

Device

three tubes (6 teaspoons) of peripheral blood are drawn and are analyzed using the CTC chip

Other names: Herringbone circulating tumor cell chip, herringbone CTC chip, HBCTC chip

Primary outcomes

  1. Number of patients with detectable EGFR mutations in their CTCs

    Time frame: 2 years

    Calculate the number of patients in the study population with detectable EGFR mutations in the CTCs in order to demonstrate the feasibility of testing for EGFR mutations from captured CTCs

  2. Number of patients with CTC-derived EGFR genotyping matching their tumor-derived EGFR genotyping

    Time frame: 2 yearss

    Determine the concordance of EGFR genotyping from CTCs compared to tumor tissue

Secondary outcomes

  1. Number of patients with EGFR gentoype results detectable from plasma cfDNA

    Time frame: 2 years

    Explore the feasibility of EGFR genotyping from plasma circulating free DNA (cfDNA)

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • Dana-Farber Cancer Institute
  • M.D. Anderson Cancer Center
  • Memorial Sloan Kettering Cancer Center

Registry information

Important dates

Study start
2012
Primary completion
2016
Study completion
2016
First posted
Nov 28, 2012
Registry last updated
Sep 26, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.